Gracell Biotechnologies ADR (GRCL) sponsored is a great pick for ‘Trends’ investors, here’s why

Most of us have heard the phrase “the trend is your friend.” And this is undoubtedly the key to success when it comes to short-term investing or trading. But it is not easy to ensure the sustainability of a trend and to profit from it.

Often, the direction of the stock’s price movement reverses quickly after taking a position in it, causing investors to suffer a short-term capital loss. So it is important to ensure that there are enough factors – like solid fundamentals, positive revisions to the earnings forecast, etc. – which can support the stock’s momentum.

Investors looking to profit from stocks that are currently moving may find our Last Price Strength screen quite useful. This predefined screen is useful for spotting stocks that are in an uptrend, supported by the strength of their fundamentals, and are trading at the top of their 52-week range low, which is usually a bullish indicator.

There are several stocks that have passed through the screen and Gracell Biotechnologies Inc. Sponsored ADR (GRCL) is one of them. Here are the main reasons why this stock is a solid pick for “trending” investing.

A solid 12-week price increase reflects investors’ continued willingness to pay more for the stock’s potential upside. GRCL is quite relevant in this regard, gaining 98.4% during this period.

However, it is not enough to look at the price change over three months or so, as it does not reflect any trend reversal that may have occurred in a shorter period of time. It is important for a potential winner to maintain the price trend. The 14.2% price increase over the past four weeks ensures that the trend is still in place for this company’s stock.

Moreover, GRCL is currently trading at 83.2% of its 52-week High-Low Range, hinting that it may be on the verge of a breakout.

Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), meaning it is in the top 20% of more than 4,000 stocks we rank based on trends in earnings estimate revisions and EPS surprises—the key factors that affect the movement of share prices in the short term.

The Zacks Rank stock rating system, which uses four factors related to earnings estimates to classify stocks into five groups ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive external audited track record, the Zacks #1 Rank stock has generated an average annual return of +25% since 1988. You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here >>>>

Another factor that confirms the company’s fundamental strength is its average #1 Broker Recommendation (Strong Buy). This indicates that the brokerage community is very optimistic about the short-term price performance of the stock.

So the price trend in GRCL may not reverse soon.

In addition to GRCL, there are several other stocks that are currently passing through our Last Power Price screen. You might consider investing in them and start looking for the latest stocks that meet these criteria.

This isn’t the only screen that can help you find your next winning stock pick. Based on your personal investing style, you can choose from over 45 Zacks Premium Screens that are strategically designed to beat the market.

Keep in mind, however, that the key to a successful stock-picking strategy is to ensure that it has produced profitable results in the past. You can easily do this using the Zacks Research Advisor. In addition to allowing you to test the effectiveness of your strategy, the program comes with some of our most successful stock picking strategies.

Click here to sign up for a free trial of Research Advisor today.

Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report

Sponsored by Gracell Biotechnologies Inc. ADR (GRCL): Free Stock Analysis Report

To read this Zacks.com article, click here.

Zacks Investment Research

Leave a Comment

Your email address will not be published. Required fields are marked *